

PROGENICS PHARMACEUTICALS INC
 Form 3
 June 06, 2005

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â Boyd Thomas A (Last) (First) (Middle)	2. Date of Event Requiring Statement (Month/Day/Year) 06/06/2005	3. Issuer Name and Ticker or Trading Symbol PROGENICS PHARMACEUTICALS INC [PGNX]	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) Sr VP, Product Development	5. If Amendment, Date Original Filed(Month/Day/Year)
---	--	---	--	--

PROGENICS
 PHARMACEUTICALS,
 INC., Â 777 OLD SAW MILL
 RIVER ROAD
 (Street)

TARRYTOWN, Â NY Â 10591
 (City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	13,176	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security	4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership
---	---	--	---------------------------	----------------------	--

Edgar Filing: PROGENICS PHARMACEUTICALS INC - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Non-Qualified Stock Options (right to buy)	06/28/2001 ⁽¹⁾	06/27/2010	Common Stock	15,000	\$ 13.625	D	Â
Non-Qualified Stock Options (right to buy)	01/17/2000 ⁽¹⁾	01/17/2010	Common Stock	15,000	\$ 17.19	D	Â
Non-Qualified Stock Options (right to buy)	01/01/2003 ⁽¹⁾	12/31/2011	Common Stock	50,000	\$ 18.47	D	Â
Non-Qualified Stock Options (right to buy)	07/01/2003 ⁽²⁾	06/30/2012	Common Stock	20,000	\$ 12.29	D	Â
Non-Qualified Stock Options (right to buy)	07/01/2004 ⁽²⁾	06/30/2013	Common Stock	25,000	\$ 15.06	D	Â
Non-Qualified Stock Options (right to buy)	07/01/2005	10/01/2005	Common Stock	358 ⁽³⁾	\$ 16.81 ⁽⁴⁾	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Boyd Thomas A PROGENICS PHARMACEUTICALS, INC. 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591	Â	Â	Â Sr VP, Product Development	Â

Signatures

Robert A. McKinney 06/06/2005

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock options become exercisable in five equal installments, commencing on the date exercisable
- (2) The stock options become exercisable in four equal installments, commencing on the date exercisable
- (3) The number of shares may vary with the actual salary paid to the optionee between the period April 1 and June 30
- (4) The exercise price per share for the options shall be the lesser of this amount or 85% of the fair market value of the Common Stock on the date of exercise

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.